Literature DB >> 28988028

Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.

Kristen Pepin1, Amy Bregar2, Michelle Davis3, Alexander Melamed2, Emily Hinchcliff4, Allison Gockley3, Neil Horowitz3, Marcela G Del Carmen2.   

Abstract

OBJECTIVE: Admissions to intensive care units (ICU) are costly, but are necessary for some patients undergoing radical cancer surgery. When compared to primary debulking surgery (PDS), neoadjuvant chemotherapy (NACT) with interval debulking surgery, is associated with less peri-operative morbidity. In this study, we compare rates, indications and lengths of ICU stays among ovarian cancer patients admitted to the ICU within 30days of cytoreduction, either primary or interval.
METHODS: A retrospective chart review was performed of patients with stage III-IV ovarian cancer who underwent surgical cytoreduction at two large academic medical centers between 2010 and 2014. Chi square tests, Student t-tests, and Mann-U Whitney tests were used.
RESULTS: A total of 635 patients were included in the study. There were 43 ICU admissions, 7% of patients. Compared to NACT, a higher percentage of PDS patients required ICU admission, 9.4% vs 3.9% of patients (P=0.004). ICU admission indications did not vary between PDS and NACT patients. NACT patients admitted to the ICU had comparable mean surgical complexity scores to those PDS patients admitted to the ICU, 6.2 (95%CI 5.3-7.1) vs 4.5 (95%CI 3.1-6.0) (P=0.006). Length of ICU admission did not vary between groups, PDS 2.7days (95%CI 2.3-3.2) vs 3.5days (95%CI 1.5-5.6) for NACT (P=0.936).
CONCLUSIONS: The rate of ICU admissions among patients undergoing PDS is higher than for NACT. Among patients admitted to the ICU, indications for admission, length of stay and surgical complexity were similar between patients treated with NACT and PDS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytoreduction; Intensive care; Neoadjuvant; Surgical complexity

Mesh:

Year:  2017        PMID: 28988028     DOI: 10.1016/j.ygyno.2017.09.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  National trends in bowel and upper abdominal procedures in ovarian cancer surgery.

Authors:  Joseph A Dottino; Weiguo He; Charlotte C Sun; Hui Zhao; Shuangshuang Fu; Jose Alejandro Rauh-Hain; Rudy S Suidan; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Int J Gynecol Cancer       Date:  2020-07-02       Impact factor: 3.437

2.  Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.

Authors:  Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Christa D Niehot; Heleen J van Beekhuizen
Journal:  J Gynecol Oncol       Date:  2022-06-07       Impact factor: 4.756

Review 3.  Postoperative Admission in Critical Care Units Following Gynecologic Oncology Surgery: Outcomes Based on a Systematic Review and Authors' Recommendations.

Authors:  Nikolaos Thomakos; Anastasia Prodromidou; Dimitrios Haidopoulos; Nikolaos Machairas; Alexandros Rodolakis
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 4.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

5.  A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

Authors:  Eleonora Ghisoni; Dionyssios Katsaros; Furio Maggiorotto; Massimo Aglietta; Marco Vaira; Michele De Simone; Gloria Mittica; Gaia Giannone; Manuela Robella; Sofia Genta; Fabiola Lucchino; Francesco Marocco; Fulvio Borella; Giorgio Valabrega; Riccardo Ponzone
Journal:  J Ovarian Res       Date:  2018-05-30       Impact factor: 4.234

6.  Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery.

Authors:  Christopher G Smith; Daniel L Davenport; Justin Gorski; Anthony McDowell; Brian T Burgess; Tricia I Fredericks; Lauren A Baldwin; Rachel W Miller; Christopher P DeSimone; Charles S Dietrich; Holly H Gallion; Edward J Pavlik; John R van Nagell; Frederick R Ueland
Journal:  Healthcare (Basel)       Date:  2019-07-03

7.  Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.

Authors:  Li-Yuan Feng; Sheng-Bin Liao; Li Li
Journal:  J Ovarian Res       Date:  2020-02-12       Impact factor: 4.234

8.  Machine Learning-Based Risk Prediction of Critical Care Unit Admission for Advanced Stage High Grade Serous Ovarian Cancer Patients Undergoing Cytoreductive Surgery: The Leeds-Natal Score.

Authors:  Alexandros Laios; Raissa Vanessa De Oliveira Silva; Daniel Lucas Dantas De Freitas; Yong Sheng Tan; Gwendolyn Saalmink; Albina Zubayraeva; Racheal Johnson; Angelika Kaufmann; Mohammed Otify; Richard Hutson; Amudha Thangavelu; Tim Broadhead; David Nugent; Georgios Theophilou; Kassio Michell Gomes de Lima; Diederick De Jong
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.